Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Almost a full year after Incyte broke off a troubled partnership with Eli Lilly to focus on its own internal engine, one of the drugs from that engine will enter the market.
Pemigatinib, now branded as Pemazyre, obtained FDA approval as a second-line treatment for a rare form of cancer known as cholangiocarcinoma, or bile duct cancer. For Incyte, a biotech that rose to prominence on the strength of a single drug — Jakafi — and a slew of Big Pharma partnerships, the approval marks the first of what they hope will be a series of internal successes and the first sign of a new phase for the company, albeit one that is unlikely to make a huge commercial splash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
